No 02 2019

The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.

In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer.

Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.

Getinge has acquired Pennamed, a UK-based distributor of endoscopic consumables serving National Health Service (NHS) and independent healthcare providers.

The exercise period for warrants of series TO1 in Isofol ended on 30 March 2026 and the outcome shows that a total of 37,301,067 TO1 were exercised for subscription of 37,301,067 new shares, corresponding to a subscription rate of approximately 93.57 per cent.

A new study from the University of Gothenburg may help guide the development of better influenza vaccines. 

A new COVID‑19 variant nicknamed Cicada (BA.3.2) is spreading internationally, with early data indicating notable immune escape but no clear evidence of more severe disease than current strains.